Kingmed Diagnostics(SH:603882) Xin Lang Cai Jing·2026-01-07 02:49Core Viewpoint - The stock price of Kingmed Diagnostics has shown fluctuations, with a recent decline of 2.01% and a total market value of 13.773 billion yuan, while the company has experienced a year-to-date increase of 4.83% in stock price [1]. Group 1: Financial Performance - For the period from January to September 2025, Kingmed Diagnostics reported a revenue of 4.538 billion yuan, representing a year-on-year decrease of 19.23% [2]. - The net profit attributable to the parent company for the same period was -796.095 million yuan, reflecting a significant year-on-year decline of 184.84% [2]. Group 2: Shareholder Information - As of September 30, 2025, the number of shareholders for Kingmed Diagnostics was 41,700, which is a decrease of 1.60% compared to the previous period [2]. - The average number of circulating shares per shareholder increased by 1.62% to 11,042 shares [2]. Group 3: Business Overview - Kingmed Diagnostics, established on May 26, 2006, and listed on September 8, 2017, provides a wide range of diagnostic services to over 23,000 medical institutions across China, covering nearly 80 types of testing technologies and approximately 3,200 testing projects [1]. - The company's main business revenue composition includes medical diagnostic services at 91.20%, sales of diagnostics at 6.45%, and other services at 1.47% [1]. Group 4: Institutional Holdings - As of September 30, 2025, Hong Kong Central Clearing Limited was the second-largest circulating shareholder, holding 35.5057 million shares, a decrease of 2.8676 million shares from the previous period [3]. - The eighth-largest circulating shareholder, Hua Bao Zhong Zheng Medical ETF, held 7.8786 million shares, down by 1.2515 million shares compared to the previous period [3].